P7-9. Pembrolizumab +- sacituzumab govitecan for 1L metastatic NSCLC : KEYNOTE-D46 / EVOKE-03 study von Isamu Okamoto, Mor Moskovitz, Peng Chen, Jilpa Patel, Sabeen Mekan, M.Catherine Pietanza, Yalin Zhu, Renata Eiras, Marcello Tiseo

Volltext

EN3-2. Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of NSCLC von Naoyuki Nogami, Delvys Rodriguez-Abreu, Yi-Long Wu, Michael Boyer, Marina C.Garassino, Tony S.K. Mok, Ying Cheng, Rina Hui, Dariusz M.Kowalski, Andrew G.Robinson, Julie R.Brahmer, Ticiana A.Leal, Gilberto Lopes, Byoung Chul Cho, Silvia Novello, Nir Peled, Gilberto de Castro Jr, Melanie A.Leiby, Diana Chirovsky, Jianxin Lin, M.Catherine Pietanza

Volltext